Danish Lundbeck’s Brexpiprazole Could Reach U.S. Market In 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
But the CNS disease specialist also expects the continuing loss of marketing exclusivity on key products and product launch costs to hold back revenue growth and profits in 2015 that will not be fully compensated by sales from multiple new product launches around the world.
You may also be interested in...
Deal Watch: Lundbeck Acquires Chelsea As Industry Awaits Possible AstraZeneca, Allergan Buyouts
Merck sells off its consumer business to Bayer AG in a deal in which the two companies also will co-develop and co-commercialize sGC modulator drugs. Lundbeck buys out Chelsea and its recently approved dizziness drug Northera.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.